Express News | HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Express News | Needham Reiterates Buy on NextCure, Maintains $4 Price Target
Express News | NextCure Q1 EPS $(0.61) Misses $(0.59) Estimate
Express News | NextCure Inc: Cash of Approximately $96.0 Mln Expected to Fund Operations Into Second Half of 2026
NextCure 1Q Loss/Shr 61c >NXTC
NextCure 1Q Loss/Shr 61c >NXTC
Express News | NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Promising Clinical Outlook for NextCure's Novel ADC LNCB74 Spurs Buy Rating
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceuti
Press Release: NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
NextCure Is Maintained at Buy by HC Wainwright & Co.
NextCure Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on NextCure, Raises Price Target to $8
NextCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 323.17% HC Wainwright & Co. $5 → $8 Maintains Buy 03/20/2024 111.58% Needham $4 → $4 Maintains
NextCure Is Maintained at Buy by Needham
NextCure Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on NextCure, Maintains $4 Price Target
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersYield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics
Express News | NextCure Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY23 EPS Results
NextCure GAAP EPS of -$2.25 Beats by $0.02
No Data